- Home
- GOEV vs CELU Comparison
GOEV vs CELU Comparison
Compare GOEV & CELU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GOEV
- CELU
- Stock Information
- Founded
- GOEV 2017
- CELU 2016
- Country
- GOEV United States
- CELU United States
- Employees
- GOEV N/A
- CELU N/A
- Industry
- GOEV
- CELU Biotechnology: Pharmaceutical Preparations
- Sector
- GOEV
- CELU Health Care
- Exchange
- GOEV Nasdaq
- CELU Nasdaq
- Market Cap
- GOEV 34.3M
- CELU 40.9M
- IPO Year
- GOEV N/A
- CELU N/A
- Fundamental
- Price
- GOEV $0.50
- CELU $2.46
- Analyst Decision
- GOEV Strong Buy
- CELU
- Analyst Count
- GOEV 6
- CELU 0
- Target Price
- GOEV $22.71
- CELU N/A
- AVG Volume (30 Days)
- GOEV 8.8M
- CELU 3.1M
- Earning Date
- GOEV 11-13-2024
- CELU 11-07-2024
- Dividend Yield
- GOEV N/A
- CELU N/A
- EPS Growth
- GOEV N/A
- CELU N/A
- EPS
- GOEV N/A
- CELU N/A
- Revenue
- GOEV $1,864,000.00
- CELU $42,690,000.00
- Revenue This Year
- GOEV $2,999.89
- CELU N/A
- Revenue Next Year
- GOEV $1,016.40
- CELU $233.89
- P/E Ratio
- GOEV N/A
- CELU N/A
- Revenue Growth
- GOEV 259.15
- CELU 182.02
- 52 Week Low
- GOEV $0.37
- CELU $1.30
- 52 Week High
- GOEV $8.81
- CELU $7.97
- Technical
- Relative Strength Index (RSI)
- GOEV 36.38
- CELU 49.49
- Support Level
- GOEV $0.48
- CELU $3.26
- Resistance Level
- GOEV $0.76
- CELU $4.34
- Average True Range (ATR)
- GOEV 0.11
- CELU 0.84
- MACD
- GOEV 0.01
- CELU 0.11
- Stochastic Oscillator
- GOEV 24.32
- CELU 29.59
About GOEV Canoo Inc.
Canoo Inc is a mobility technology company providing with a proprietary modular electric vehicle platform and connected services initially focused on commercial fleet, government and military customers. The Company has developed a breakthrough EV platform that it believes will enable it to rapidly iterate and bring new products, addressing multiple use cases, to market faster than competition and at lower cost.
About CELU Celularity Inc.
Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from bio-banking segment.